Cargando…

Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) is the most common inherited human myopathy. Typically, the secondary process involving severe inflammation and necrosis exacerbate disease progression. Previously, we reported that the NLRP3 inflammasome complex plays a crucial role in this disorder. Mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dubuisson, Nicolas, Davis-López de Carrizosa, María A., Versele, Romain, Selvais, Camille M., Noel, Laurence, Van den Bergh, P. Y. D., Brichard, Sonia M., Abou-Samra, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9770793/ https://www.ncbi.nlm.nih.gov/pubmed/36569900 http://dx.doi.org/10.3389/fimmu.2022.1049076

Ejemplares similares

Histological Methods to Assess Skeletal Muscle Degeneration and Regeneration in Duchenne Muscular Dystrophy
por: Dubuisson, Nicolas, et al.
Publicado: (2022)

Walking down Skeletal Muscle Lane: From Inflammasome to Disease
por: Dubuisson, Nicolas, et al.
Publicado: (2021)

AdipoRon, a new therapeutic prospect for Duchenne muscular dystrophy
por: Abou‐Samra, Michel, et al.
Publicado: (2020)

Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy
por: Boursereau, Raphaël, et al.
Publicado: (2018)

Inhibiting the NLRP3 Inflammasome With MCC950 Ameliorates Isoflurane-Induced Pyroptosis and Cognitive Impairment in Aged Mice
por: Fan, Yunxia, et al.
Publicado: (2018)

The Adiponectin Receptor Agonist, ALY688: A Promising Therapeutic for Fibrosis in the Dystrophic Muscle
por: Dubuisson, Nicolas, et al.
Publicado: (2023)

Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin
por: Lecompte, S., et al.
Publicado: (2017)

AdipoRon enhances healthspan in middle‐aged obese mice: striking alleviation of myosteatosis and muscle degenerative markers
por: Selvais, Camille M., et al.
Publicado: (2022)

The selective NLRP3 inhibitor MCC950 hinders atherosclerosis development by attenuating inflammation and pyroptosis in macrophages
por: Zeng, Wenyun, et al.
Publicado: (2021)

Targeting the NLRP3 Inflammasome With Inhibitor MCC950 Prevents Aortic Aneurysms and Dissections in Mice
por: Ren, Pingping, et al.
Publicado: (2020)

Adiponectin and Its Mimics on Skeletal Muscle: Insulin Sensitizers, Fat Burners, Exercise Mimickers, Muscling Pills … or Everything Together?
por: Abou-Samra, Michel, et al.
Publicado: (2020)

Inhibiting the NLRP3 Inflammasome Activation with MCC950 Ameliorates Diabetic Encephalopathy in db/db Mice
por: Zhai, Yadong, et al.
Publicado: (2018)

Selective NLRP3 Inflammasome Inhibitor MCC950 Suppresses Inflammation and Facilitates Healing in Vascular Materials
por: Grant, Angus J., et al.
Publicado: (2023)

The Small Molecule NLRP3 Inflammasome Inhibitor MCC950 Does Not Alter Wound Healing in Obese Mice
por: Lee, James S., et al.
Publicado: (2018)

Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease
por: Østergaard, Jakob A., et al.
Publicado: (2022)

A Probe for NLRP3 Inflammasome Inhibitor MCC950 Identifies Carbonic Anhydrase 2 as a Novel Target
por: Kennedy, Cassandra R., et al.
Publicado: (2021)

MCC950 closes the active conformation of NLRP3 to an inactive state
por: Tapia-Abellán, Ana, et al.
Publicado: (2019)

MCC950 ameliorates ventricular arrhythmia vulnerability induced by heart failure
por: Jiang, Xiaobo, et al.
Publicado: (2022)

MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice
por: Perera, Agampodi Promoda, et al.
Publicado: (2018)

A small molecule inhibitor MCC950 ameliorates kidney injury in diabetic nephropathy by inhibiting NLRP3 inflammasome activation
por: Zhang, CongXiao, et al.
Publicado: (2019)

MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation
por: Jiang, Maorong, et al.
Publicado: (2020)

NLRP3 inflammasome inhibitor MCC950 can reduce the damage of pancreatic and intestinal barrier function in mice with acute pancreatitis
por: Shen, Yanghui, et al.
Publicado: (2022)

Inflammasome Activity in the Skeletal Muscle and Heart of Rodent Models for Duchenne Muscular Dystrophy
por: Onódi, Zsófia, et al.
Publicado: (2023)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Vande Walle, Lieselotte, et al.
Publicado: (2019)

Intraperitoneal Injection of MCC950 Inhibits the Progression of Myopia in Form-Deprivation Myopic Mice
por: Chen, Zhengyu, et al.
Publicado: (2023)

Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy
por: Marrocco, V., et al.
Publicado: (2017)

Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death
por: Matsuoka, Taisuke, et al.
Publicado: (2020)

NLRP3 inflammasome inhibitor MCC950 attenuates primary dysmenorrhea in mice via the NF-κB/COX-2/PG pathway
por: Tang, Biao, et al.
Publicado: (2020)

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition
por: Walle, Lieselotte Vande, et al.
Publicado: (2019)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b2e0kohpo6hm1rsj6l3cimtgpd